Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Detecting Bone Marrow Involvement in DLBCL

Clin Lymphoma Myeloma Leuk; ePub 2017 Jun 16; Vishnu, et al

Publish date:: June 28, 2017

PET-CT can accurately detect lymphomatous bone marrow involvement in patients with diffuse large B cell lymphoma (DLBCL), according to a study involving 90 individuals. Participants were diagnosed with DLBCL between 2004 and 2013. Investigators looked for bone marrow involvement using PET-CT with and without the contribution of bone marrow aspirate/biopsy (BMAB). Among the results:

One-fourth of patients had bone marrow involvement established by PET-CT; 14% by BMAB; and 12% by both methods.
Half of the patients with positive PET-CT had bone marrow involvement by DLBCL.
Only 3% with negative PET-CT showed bone marrow involvement.
BMAB upstaged 2% of stage I/II patients to stage IV.
The sensitivity and specificity of PET-CT to detect bone marrow involvement by DLBCL was 86% and 87%, respectively.
The positive predictive value of PET-CT was only 50%, while the negative predictive value was 98%.

Citation:

Vishnu P, Wingerson A, Lee M, Mandelson M, Aboulafia D. Utility of bone marrow biopsy and aspirate for staging of diffuse large B cell lymphoma in the era of positron emission tomography with 2-deoxy-2-[fluorine-18] fluoro-d-glucose integrated with computed tomography. [Published online ahead of print June 16, 2017]. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2017.06.010.

This Week's Must Reads

Phase II Trial of DNA Vaccine Encoding PAP in Patients with PCa ,

Utilization of Surgery for Post-prostatectomy Incontinence,

Claims Analysis of Advanced PCa Treatment Costs and Resource Use,

Testosterone Therapy Doesn't Increase Prostate Cancer Risk,

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced PCa,

Must Reads in Lymphoma & Plasma Cell Disorders

Cardiac assessment before doxorubicin treatment , Enns DL et al. Mayo Clin Proc Innov Qual Outcomes. 2018 Aug 3;2(3):277-85

Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10

Outcomes Post-AlloSCT in DHL/DEL Lymphomas, Biol Blood Marrow Transplant; ePub 2017 Nov 28; Herrera, et al

Anthracycline-Related CV Dysfunction Evaluated, Cancer; ePub 2017 Nov 7; Armenian, Mertens, et al

Adcetris Approved for Primary Cutaneous ALCL, FDA news release; 2017 Nov 9